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SUMMARY
Background
Since 1970, there has been a 400% increase in liver-related deaths due to
the increasing prevalence of chronic liver disease in the United Kingdom
(UK). The 2013 UK National Confidential Enquiry into Patient Outcome
and Death report found that only 47% of patients who died from alcohol-
related liver disease received ‘good care’ during their hospital stay.
Aim
To develop a ‘care bundle’ for patients with decompensated cirrhosis, aim-
ing to ensure that evidence-based treatments are delivered within the first
24 h of hospital admission.
Methods
This work gives practical advice about how to implement the bundle and
examines its effects on patient care at three National Health Service Hospi-
tal Trusts in the UK by collecting data on patient care before and after
introduction of the bundle.
Results
Data were collected on 228 patients across three centres (59% male, median
age 53 years). Alcohol-related liver disease was the aetiology of chronic
liver disease in 85% of patients. The overall mortality rate during hospital
admission was 15%. The audits demonstrated improvements in patient care
for patients with a completed care bundle who were significantly more
likely to have a diagnostic ascitic performed within the first 24 h
(P = 0.020), have an accurate alcohol history documented (P < 0.0001) and
be given antibiotics as prophylaxis against infection following a variceal
haemorrhage (P = 0.0096). In Newcastle, the bundle completion rate
increased from 25% to 90% during the review periods.
Conclusions
The introduction of a care bundle was associated with increased rates of
diagnostic paracentesis and antibiotic prophylaxis with variceal haemor-
rhage in patients with decompensated cirrhosis.
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INTRODUCTION
In the UK, there has been a dramatic increase in the
prevalence of chronic liver disease over the last few dec-
ades, which has resulted in a substantial increase (400%
since 1970) in liver-related deaths.1, 2 There are also sig-
nificant issues with variability in management of decom-
pensated liver disease. The Lancet commission
‘Addressing liver disease in the UK’ in 2014,3 described
the ‘postcode lottery of specialist hepatology services and
centres’ with large variation in in-hospital mortality rates
for cirrhosis and liver failure across the country. Data
from Dr Foster, a healthcare variation and benchmarking
analyst, showed that for nonelective liver admissions
between 2003 and 2013 mortality rates in nonspecialist
acute hospital Trusts varied between approximately 15–
35%.3 The All Party Parliamentary Hepatology Group
(APPHG) raised ‘grave concerns about patchy service
provision across the country’.4 Liver disease is also hav-
ing an increased impact on younger people. Worryingly,
data from the Global Burden of Diseases, Injuries and
Risk Factors Study 2010 showed that for people aged
20–54 years cirrhosis has risen from the 8th leading
cause of years of life lost (YLL) in 1990 to the 3rd lead-
ing cause by 2010.5
Decompensation of cirrhosis occurs when there is an
acute deterioration in liver function in a patient with cir-
rhosis.6 Common presenting features include jaundice,
coagulopathy, ascites, hepatic encephalopathy, acute kid-
ney injury (AKI) and gastrointestinal (GI) bleeding.7
Patients with decompensated liver cirrhosis and organ
failure are considered to have acute on chronic liver fail-
ure (ACLF), which carries an approximately 30% 28-day
mortality rate.8 Following the in-hospital diagnosis of
alcohol-related cirrhosis, patients have a 30% 1-year and
60% 5-year mortality rate, respectively.9 In 2013, ‘Mea-
suring the Units’, a UK National Confidential Enquiry
into Patient Outcome and Death (NCEPOD) report
raised concerns about suboptimal care of patients in hos-
pital with complications of cirrhosis due to alcohol-
related liver disease (ARLD).10 This report found that
only 47% of patients who died from alcohol-related liver
disease received ‘good care’ during their hospital stay,
and avoidable deaths were identified. Similar findings
were found in a region-wide audit from the North East
of England.11
The authors of the NCEPOD report recommended
that a ‘toolkit’ for the acute management of patients
admitted with decompensated liver disease be developed
and made widely available.10 As a result, we developed a
‘care bundle’ for patients admitted with decompensated
cirrhosis to ensure that effective evidence-based treat-
ments are delivered within the first 24 h of admission to
hospital.6, 12 This care bundle provides a simple checklist
of key investigations, and clear guidance on the manage-
ment of cirrhosis-related complications, such as sponta-
neous bacterial peritonitis (SBP), variceal bleeding and
acute kidney injury. The bundle is designed to help
junior doctors and nonspecialists provide effective care
for these patients, who frequently have complex medical
needs, in the first 24 h, when specialist advice may not
be available. Our aim was to assess the effect of the
implementation of the care bundle on the care of
patients admitted with decompensated cirrhosis at three
National Health Service (NHS) Hospital Trusts in the
UK.
MATERIALS AND METHODS
Development of the care bundle
SMc led the development of the care bundle on behalf of
the British Society of Gastroenterology (BSG) and British
Association for the Study of the Liver (BASL) between
November 2013 and March 2014. The care bundle was
developed primarily to address the first 24 h of hospital
admission and is recommended to commence within 6 h
of hospital admission. It comprises a simple checklist to
ensure important initial investigations are conducted. In
addition, the bundle provides specific ‘step by step’ guid-
ance on the management of infections, spontaneous bac-
terial peritonitis, gastrointestinal bleeding and acute
kidney injury, so that evidence-based treatments are
delivered in a timely fashion, when specialist input may
not be available. The evidence base for all the recommen-
dations in the bundle was reviewed by McPherson et al.6
The bundle was deliberately kept simple so that it can be
completed quickly. It can be filed in the patient’s notes
and can also serve as an audit tool to assess patient man-
agement. The care bundle is freely available at (http://
www.bsg.org.uk/care-bundles/care-bundles-general/decom
pensated-cirrhosis-care-bundle-first-24-hours.html). It has
now been endorsed by the BSG and BASL and is recom-
mended for use in all hospitals in the UK.3, 12, 13
Implementation of the care bundle in Newcastle
The care bundle was introduced in Newcastle upon Tyne
Hospitals NHS Foundation Trust (NUTH) in March
2014. Development and implementation of the care
bundle was adopted as one of the Trust’s major Com-
missioning by Quality and Innovation (CQUIN)
improvement projects for 2014/15. It was divided into
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four areas: development of the bundle and implementa-
tion in pilot areas, review of the pilot with an action
plan to roll it out across the Trust, 70% target for bundle
completion and re-audit with an 85% completion target.
The total value of this CQUIN for completion of all
milestones was £850 000. Full details of the CQUIN tar-
gets for the care bundle implementation are shown in
Table S1. The hospital clinical governance department
and the hospital medical records committee approved its
introduction.
The majority of patients with decompensated chronic
liver disease are admitted via the medical admissions
suite at the Royal Victoria Infirmary (RVI), where acute
medicine physicians initially manage them for the first
24 h. The medical admissions suite was therefore the
main focus for the implementation of the care bundle.
The care bundle was published on the hospital intranet
and all hospital clinicians were informed of its intro-
duction via email from the lead clinician. Targeted edu-
cation sessions were delivered at the Trust clinical
governance meeting, medical specialist registrar teach-
ing, medical admissions suite staff teaching sessions and
Foundation and Core Medical trainees teaching. Since
the initial education sessions, regular updates on pro-
gress have been delivered to medical trainees and
consultants.
Review of impact of the implementation of the care
bundle in Newcastle
A retrospective review of the management of consecutive
patients admitted with decompensated cirrhosis to the
medical admissions suite at the RVI was conducted at
baseline [pre-care bundle introduction; September 2013
to February 2014 (6 months)] and following the intro-
duction of the care bundle over two time periods [May
to July 2014 (3 months) and November 2014 to June
2015 (8 months)] with on-going targeted education ses-
sions throughout this period. Discharge summaries for
patients admitted during this time period were reviewed
to identify patients admitted with decompensated cirrho-
sis. Patients were included if they had known cirrhosis
or suspected cirrhosis and were admitted with jaundice,
hepatic encephalopathy, ascites, sepsis or variceal bleed-
ing. A data collection tool (Data S1) was used that
included all parameters addressed in the ‘care bundle’
(initial investigations, management of complications such
as spontaneous bacterial peritonitis, acute kidney injury,
length of stay, mortality). Data were collected from
review of the medical case-notes and electronic records
for each patient. As the care bundle is primarily aimed
at providing advice for the nonspecialist, patients admit-
ted directly to the tertiary liver unit were not included in
the audits as they are reviewed by a hepatology registrar
on admission.
Implementation and review of the care bundle in two
other UK Hospitals
Royal Cornwall Hospitals NHS Trust. The care bundle
was implemented in the Royal Cornwall Hospitals
(RCH) NHS Trust, a large District General Hospital
(DGH), in May 2015. Prior to its implementation
teaching sessions were delivered to all emergency and
acute medicine clinicians. The care bundle was made
available on the hospital software ‘MAXIMS’. Clinicians
also received regular reminder emails advising of them
to use the care bundle for all patients admitted with
decompensated liver disease. A retrospective baseline
(pre-bundle) review was conducted of consecutive
admissions of patients admitted with decompensated
cirrhosis between January and April 2015 (4 months).
A second review was conducted following the introduc-
tion of the bundle between September and December
2015 (4 months). The same methodology was used as
in Newcastle.
City Hospitals Sunderland NHS Foundation Trust. The
care bundle was introduced in City Hospitals Sunderland
(CHS) NHS Foundation Trust, another large District
General Hospital, in September 2014. Introduction of the
bundle was also adopted as a local Commissioning by
Quality and Innovation target. All acute medical staff
received training on the bundle. Since the initial intro-
duction of the care bundle, an electronic version has
been developed that can be completed directly on their
hospital computer system. This will help generate long-
term data collection on the use of the care bundle. Data
were collected over a 4-month period (September to
December 2013), prior to the introduction of the bundle,
to collect a baseline assessment of the management of
patients with decompensated cirrhosis. Following the
introduction of the care bundle, data were collected for a
3-month period (February to April 2015). All the data
were collected using the same methodology as in New-
castle.
Analysis methods
All statistical analyses were performed using SPSS software
version 22.0 (SPSS Inc, Chicago, IL, USA). Variables
were summarised as median and range. Fisher’s exact
test was used to determine the distribution of categorical
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variables between groups and Mann–Whitney U-test for
continuous variables.
RESULTS
Description of whole cohort
In total, data were collected on 228 patients across the
three centres. Of this whole cohort, 59% were male with
a median age of 53 years (range 31–87). Alcohol-related
liver disease (ARLD) was the most common aetiology of
liver disease, accounting for 85% of patients and 89%
were already known to have chronic liver disease prior
to admission. The median model for end-stage liver dis-
ease (MELD) and Child–Pugh scores were 18 (range
6–45) and 9 (range 5–14), respectively. The overall mor-
tality rate during hospital admission was 15% with a
median length of stay of 11 days (range 1–139). Table 1
shows the demographics of the patients at each centre.
The aetiology of chronic liver disease was alcohol-related
liver disease in over 80% of patients in all centres (Fig-
ure 1). The commonest reason for hospital admission
was ascites (34%), with hepatic encephalopathy and sus-
picion of upper gastrointestinal bleeding each accounting
for a further 20% of admissions (Table 2).
Bundle completion rates in Newcastle
Following introduction of the care bundle in Newcastle
in March 2014 completion rates of the bundle were low
at the first review period at only 25%. However, over
time, with repeated education sessions and raising aware-
ness of the bundle, there has been a substantial increase
in rates of bundle completion to 90% in the third review
period (Figure 2).
Impact of the introduction of the care bundle in
Newcastle
A comparison of the demographic data and clinical
management for patients with decompensated cirrhosis
admitted prior to the introduction of the bundle and
post implementation of the bundle is shown in Table 3.
Overall, patients who had a care bundle completed were
more likely to have the appropriate investigations and
management conducted than patients admitted prior to
the introduction of the care bundle and those who did
not have one completed. Post-bundle implementation,
the majority of investigations and management were
conducted appropriately. The most striking improvement
Table 1 | Demographic information for patients from
each centre
Newcastle Cornwall Sunderland
Male gender, n (%) 61 (53) 16 (76)* 33 (62)*
Age, median (range) 54 (31–87) 52 (32–78) 53 (31–85)
MELD, median (range) 17 (6–45) 20 (7–40) 16 (6–30)
NA, not available.
* Gender data not available for all patients.
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Figure 1 | Cause of liver disease according to centre.
NAFLD, nonalcoholic fatty liver disease.
Table 2 | Primary reason for admission to hospital
Clinical reason for hospital admission
Percentage
of cohort
Ascites 34
Hepatic encephalopathy 20
Upper gastrointestinal bleeding 20
Jaundice 15
Sepsis 5
Other 6
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Figure 2 | Improvement in completion rates for ‘the
care bundle’ following its implementation over
successive audit periods.
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in patient care was the rate of diagnostic ascitic tap
within 24 h of admission to exclude spontaneous bacte-
rial peritonitis, which improved from 61% to 86%. There
were also signs of improvement in the documentation of
alcohol excess, management of spontaneous bacterial
peritonitis and variceal bleeding.
Interestingly, data from Newcastle also showed that
overall, patients who had a care bundle completed had a
trend towards shorter median hospital stay [8 (2–64)
days] than prior to introduction of the care bundle [11 (2–
31) days] and post-bundle implementation when a bundle
was not completed [13 (2–100) days] [P = 0.4413].
Successful implementation of the care bundle in two
district general hospitals
Following the successful implementation of the bundle
in Newcastle and demonstrating improved patient care,
we aimed to establish if implementation of the care
bundle could have benefits more widely in other hos-
pitals. The same care bundle was implemented at the
Royal Cornwall Hospital and City Hospitals Sunder-
land. A comparison of the demographic data and
clinical management for patients with decompensated
cirrhosis admitted to these hospitals prior to the intro-
duction of the bundle and post implementation of the
bundle are shown in Table 4. Overall, there were
marked improvements in aspects of patient manage-
ment post-introduction of the care bundle, most nota-
bly in patients who had a care bundle completed.
Complete data for each individual centre are available
in Tables S2 and S3.
Improved patient care following bundle
implementation across whole cohort
A comparison of data from all three hospitals combined
is shown in Table 5. When data for all three hospitals
were combined, the most notable improvements in
patient care were seen for patients with a completed care
bundle who were significantly more likely to have a diag-
nostic ascitic performed within the first 24 h
(P = 0.020), have an accurate alcohol history docu-
mented (P < 0.0001) and be given antibiotics as prophy-
laxis against infection following a variceal haemorrhage
(P = 0.0096) (Figure 3).
Table 3 | Pre- and post-bundle audit results from Newcastle
Pre-care bundle
(n = 42)
Post-care bundle (n = 72)
Care bundle not
completed (n = 32)
Care bundle
completed (n = 40)
Median MELD 17 14.5 18.5
Diagnostic tap ≤24 h if ascites (%) 17/28 (61) 9/16 (56) 19/22 (86)
Antibiotics prescribed if SBP (%) 2/2 (100) 1/1 (100) 1/1 (100)
Albumin prescribed if SBP (%) 1/2 (50) 1/1 (100) 1/1 (100)
Alcohol consumption documented (%) 29/42 (69) 24/32 (75) 34/40 (85)
Pabrinex prescribed if appropriate (%) 25/29 (86) 19/21 (90) 22/24 (92)
CIWA prescribed if appropriate (%) 24/29 (83) 17/21 (81) 22/24 (92)
AKI on admission (%) 9/42 (21) 5/32 (16) 6/40 (15)
Diuretics/nephrotoxins stopped if AKI (%) 7/9 (78) 5/5 (100) 5/6 (83)
Appropriate fluids given if AKI (%) 8/9 (89) 5/5 (100) 6/6 (100)
Sodium <125 on admission (%) 3/42 (7) 1/32 (3) 2/40 (5)
Diuretics stopped and fluid balance if Na <125 (%) 2/3 (67) 1/1 (100) 2/2 (100)
Suspected variceal bleed (%) 2/42 (5) 6/32 (19) 4/40 (10)
Terlipressin given (%) 2/2 (100) 4/6 (67) 4/4 (100)
Antibiotics given (%) 1/2 (50) 4/6 (67) 4/4 (100)
OGD within 24 h (%) 1/2 (50) 4/6 (67) 1/2† (50)
Survived admission (%) 37/42 (88) 29/32 (91) 34/40 (85)
Median length of stay, days (range) 11 (2–31) 11.5 (2–100) 8 (2–64)
Median length of stay, days (range) – excluding
patients who died during admission
11 (2–31) 13 (2–100) 8 (2–64)
MELD, model for end-stage liver disease; SBP, spontaneous bacterial peritonitis; CIWA, clinical institute withdrawal assessment
for alcohol; AKI, acute kidney injury; Na, sodium; OGD, oesophago-gastro-duodenoscopy.
† 2 decided OGD not indicated, 1 at 28 h.
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CONCLUSIONS
There is an increasing body of data to show that the man-
agement of patients with decompensated cirrhosis in the
UK suffers from significant variability in quality across
the country. The recent National Confidential Enquiry
into Patient Outcome and Death (NCEPOD) report on
alcohol-related liver disease highlighted that the manage-
ment of some patients with decompensated cirrhosis in
the UK was suboptimal.10 As a result, we developed a
‘care bundle’ for patients admitted with decompensated
cirrhosis to help ensure the appropriate initial investiga-
tions and interventions are conducted at an early stage
when specialist advice may not be available.12 The aim of
this study was to assess the impact of introduction of this
care bundle on patient care at three UK NHS hospitals.
Overall, we found that the introduction of a care bundle
was associated with a clear improvement in the manage-
ment of patients with decompensated cirrhosis. In partic-
ular, patients who had a care bundle completed were
more likely to have accurate documentation of alcohol
consumption and have a diagnostic ascitic tap to assess
for spontaneous bacterial peritonitis. In addition, there
were improvements in the management of spontaneous
bacterial peritonitis and variceal bleeding. Importantly,
we have demonstrated that the care bundle can be imple-
mented, and lead to significant improvements in patient
care, at three different hospitals across the UK, including
a tertiary referral centre and two district general hospitals.
This is an important example of introducing evidence-
based practice into a ‘real world’ setting that has resulted
in an improvement in clinical practice with a reduction in
the variability observed. This suggests that the care bun-
dle could have wider applicability and help improve the
care of patients with decompensated liver disease admit-
ted to other hospitals in the UK and overseas.
Our experience of introducing the bundle in these
hospitals indicates that it can take time for a change to
become embedded in clinical practice. In Newcastle,
there was a gradual increase in the proportion of patients
with had a completed bundle over a 9-month period
from 25% to 90%. During the introductory period, there
was a need for repeated education sessions and rein-
forcement for clinicians until it became ‘routine’ practice.
Anecdotally, clinicians reported that once they used the
Table 4 | Pre- and post-bundle audit data for Cornwall and Sunderland combined
Pre-care bundle
(n = 50)
Post-care bundle (n = 64)
Care bundle not
completed (n = 24)
Bundle completed
(n = 40)
Median MELD 22 (6–40) 11 (9–30)* 18.5 (9–30)
Diagnostic tap ≤24 h if ascites (%) 13/21 (62) 6/7 (86) 19/23 (83)
Antibiotics prescribed if SBP (%) 3/3 (100) 0/0 (100) 2/2 (100)
Albumin prescribed if SBP (%) 3/3 (100) 0/0 (100) 1/2 (50)
Alcohol consumption documented (%) 28/50 (56) 23/24 (96) 40/40 (100)
Pabrinex prescribed if appropriate (%) 32/36 (89) 19/20 (95) 39/40 (98)
CIWA prescribed if appropriate (%) 34/36 (94) 19/20 (95) 39/40 (98)
AKI on admission (%) 11/50 (22) 6/24 (25) 7/40 (18)
Diuretics/nephrotoxins stopped if AKI (%) 11/11 (100) 4/4 (100) 5/5 (100)
Appropriate fluids given if AKI (%) 11/11 (100) 6/6 (100) 7/7 (100)
Sodium <125 on admission (%) 7/50 (14) 6/24 (25) 7/40 (18)
Diuretics stopped and fluid balance if Na <125 (%) 5/6 (83) 5/6 (83) 7/7 (100)
Suspected variceal bleed (%) 11/50 (22) 6/24 (25) 10/40 (25)
Terlipressin given (%) 9/11 (82) 4/6 (67) 10/10 (100)
Antibiotics given (%) 3/6 (50)‡ 4/6 (67) 10/10 (100)
OGD within 24 h (%) 9/11 (82) 5/6 (83) 10/10 (100)
Survived admission (%) 40/50 (80) 17/20 (85) 31/40 (80)
Median length of stay, days (range) 11 (1–139) 11 (1–139) 10 (1–62)
Median length of stay, days (range) – excluding
patients who died during admission
10.5 (1–139) 10.5 (1–139) 10 (1–60)
MELD, model for end-stage liver disease; SBP, spontaneous bacterial peritonitis; CIWA, clinical institute withdrawal assessment
for alcohol; AKI, acute kidney injury; Na, sodium; OGD, oesophago-gastro-duodenoscopy.
* MELD data not available on all patients.
‡ Antibiotic data not available for all patients.
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bundle they felt that it helped them manage patients
with decompensated cirrhosis, who they frequently found
a complex group to treat.
There were some particularly striking improvements
in patient management demonstrated by the comparison
pre- and post-bundle. The proportion of patients with
Table 5 | Summary of combined pre- and post-care bundle audit data for all 3 centres
Pre-care bundle
(n = 92)
Post-care bundle (n = 136)
Not completed
(n = 56)
Completed
(n = 80)
Median MELD 20 (6–40)* 13.5 (7–45)* 18.5 (6–42)*
Diagnostic tap ≤24 h if ascites (%) 30/49 (61) 15/23 (65) 38/45 (84)
SBP diagnosed on tap (%) 5/44 (11) 1/18 (6) 3/44 (7)
Antibiotics prescribed if SBP (%) 5/5 (100) 1/1 (100) 3/3 (100)
Albumin prescribed if SBP (%) 4/5 (80) 1/1 (100) 2/3 (67)
Alcohol consumption documented (%) 57/92 (62) 47/56 (84) 74/80 (93)
Pabrinex prescribed if appropriate (%) 57/65 (88) 38/41 (93) 61/64 (95)
CIWA prescribed if appropriate (%) 58/65 (89) 36/41 (88) 61/64 (95)
AKI on admission (%) 20/92 (22) 11/56 (20) 13/80 (16)
Diuretics/nephrotoxins stopped if AKI (%) 18/20 (90) 9/9 (100) 10/11 (91)
Appropriate fluids given if AKI (%) 19/20 (95) 11/11 (100) 13/13 (100)
Sodium <125 on admission (%) 10/92 (11) 7/56 (13) 9/80 (11)
Diuretics stopped + fluid balance if Na <125 (%) 7/9 (78) 6/7 (86) 9/9 (100)
Suspected variceal bleed (%) 13/92 (14) 12/56 (21) 14/80 (18)
Terlipressin given (%) 11/13 (85) 8/12 (67) 14/14 (100)
Antibiotics given (%) 4/8 (50)‡ 8/12 (67) 14/14 (100)
OGD within 24 h (%) 10/13 (77) 9/12 (75) 11/12 (92)
Survived admission (%) 77/92 (84) 51/56 (91) 65/80 (81)
Median length of stay, days (range) 11 (1–139) 10 (1–100) 10 (1–64)
Median LOS, days (range) – excluding
patients who died during admission
11 (1–139) 10 (1–100) 8 (2–64)
MELD, model for end-stage liver disease; SBP, spontaneous bacterial peritonitis; CIWA, clinical institute withdrawal assessment
for alcohol; AKI, acute kidney injury; Na, sodium; OGD, oesophago-gastro-duodenoscopy; LOS, length of stay.
* Age and MELD data not available for all patients.
‡ Antibiotic data not available for all patients.
120 P = 0.020 P = 0.222 P = 0.593P < 0.0001
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Figure 3 | The most notable
aspects of patient care that
were improved by introduction
of the ‘care bundle’ across the
whole cohort. Na, sodium;
OGD, oesophago-gastro-
duodenoscopy.
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ascites undergoing an ascitic tap to exclude spontaneous
bacterial peritonitis within 24 h of admission has
increased from 61% to 84% (P = 0.020). It has been
clearly demonstrated that spontaneous bacterial peritoni-
tis carries a high mortality and timely diagnosis and
treatment is vital.6 Patients with suspected variceal bleed-
ing also received improved care. Administration of terli-
pressin has increased from 85% to 100% and antibiotics
are now administered to 100% of patients as compared
to 50% in the pre-bundle audit. This compares favourably
to the recent NCEPOD report, ‘Gastrointestinal haemor-
rhage: time to get control?’, which found that 37% of
patients with variceal haemorrhage did not receive pro-
phylactic antibiotics.14 Interestingly, there has also been a
shift to earlier endoscopy with 92% of patients admitted
with gastrointestinal bleeding undergoing upper gastroin-
testinal endoscopy within 24 h of admission following the
bundle being implemented (vs. 77% in the pre-bundle
era). In all three centres, over 80% of patients had alcohol-
related liver disease and the introduction of the care bun-
dle has resulted in a significant improvement in documen-
tation of alcohol intake [62% pre-bundle compared to
93% post-bundle (P < 0.0001)].
As well as helping ensure that patients have the key
investigations conducted and treatment commenced
within the first 24 h, in Newcastle, use of the care bundle
appeared to suggest a trend towards a shorter hospital stay
(median 8 days vs. 13 days), although patients with a
completed care bundle had a higher Model for end-stage
liver disease (MELD) score (18.5 as compared with 14.5).
This suggests that prompt initiation of appropriate evi-
dence-based treatments could reduce the length of hospi-
tal admission. This difference was not reproduced at the
other centres, although their sample size was smaller.
Unfortunately, we were not able to show that completion
of the care bundle had a positive impact reducing mortal-
ity. However, the cohort was relatively small and there
were clear differences in the severity of liver disease
between the groups, which made it difficult to directly
compare mortality between groups. Patients in the ‘care
bundle’ group had higher MELD scores. This work
describes the process of successfully introducing evidence-
based care that reduces variability and it is logical to infer
that if care is delivered at a consistently high level then a
morbidity and mortality benefit will be observed if larger
numbers were included.15 Larger prospective controlled
studies may be able to assess the impact of a care bundle
on mortality.
This study does have some limitations. In particular,
the data collection was a retrospective review of medical
records, which is limited by how well the medical history
and management were documented. There was also
some missing data (gender, age and MELD score) for
Sunderland. However, the same methodology was used
throughout the study period to ensure the results were
reflective of practice change rather than changes in data
collection. Despite these limitations this study clearly
demonstrates that a standardised care bundle approach
helps ensure patients receive appropriate management
more effectively.
The importance of the development of the decompen-
sated cirrhosis care bundle was emphasised in the ‘The
Lancet Standing Commission on Liver Disease in the
UK’.3, 13 In that report it forms part of Recommendation
3, which highlights the need to focus on developing a blue-
print for improving care for acutely sick patients with liver
disease. The bundle has now been introduced in a number
of hospital trusts across the UK and it is recommended
that use of a care bundle should be a focus for audit
nationally regarding the management of patients with
decompensated cirrhosis. Quality improvement is a con-
tinuous process which demands regular audit, feedback
and education. It is also important to maintain the high
levels of compliance with bundle completion. A continu-
ous programme of education as junior doctors rotate
between posts is important. There may also be a role for
embedding the care bundle into the admission process
itself. For example, City Hospitals Sunderland have incor-
porated the bundle into their electronic admission docu-
ment (called V6) and preliminary data (not shown here)
demonstrates improved completion rates.
In conclusion, we have shown that implementation of
a care bundle for patients admitted to hospital with
decompensated cirrhosis improved rates of diagnostic
paracentesis and antibiotic prophylaxis with variceal
haemorrhage. If used more widely, a decompensated
cirrhosis care bundle might reduce variability in the
management of decompensated cirrhosis and ensure that
life-saving evidence-based treatments are given early.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Table S1. Details of the CQUIN targets for the care
bundle implementation (Total value of CQUIN for com-
pletion of all milestones was £850 000).
Table S2. Individual centre audit data from Sunder-
land.
Table S3. Individual centre audit data from Cornwall.
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Data S1. Audit tool for the management of decom-
pensated cirrhosis in the first 24 h.
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